
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine ...
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology company, today announced that an abstract highlighting interim data from its ongoing Phase 1 clinical trial …